Takeda Pharmaceutical (TAK) Gains from Investment Securities (2018 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Gains from Investment Securities of $1.4 million for Q2 2026, down 18.3% year-over-year from $1.7 million in Q2 2025, and down 65.52% quarter-over-quarter from $4.1 million in Q1 2026.
Takeda Pharmaceutical (TAK) Gains from Investment Securities (2018 - 2026) Analysis & Trends
Takeda Pharmaceutical's Gains from Investment Securities history runs 9 years deep, the most recent figure standing at $1.4 million for Q2 2026.
- In Q2 2026, Gains from Investment Securities fell 18.3% year-over-year to $1.4 million; the TTM figure through Jun 2026 stood at $8.2 million (up 81.14% YoY), while the FY2026 annual figure was $8.6 million, up 106.85% from the prior year.
- Gains from Investment Securities for Q2 2026 stood at $1.4 million, down from $4.1 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $85.4 million in Q1 2024, with the low at $6704.1 in Q3 2024.
- The 5-year median for Gains from Investment Securities is $2.3 million (2025), against an average of $8.0 million.
- The sharpest annual moves came in 2022 and 2025: Gains from Investment Securities surged 60397.32% in 2022, then plunged 99.76% in 2025.
- Takeda Pharmaceutical's Gains from Investment Securities stood at $5.8 million in 2022, then tumbled by 55.19% to $2.6 million in 2023, then climbed by 0.52% to $2.6 million in 2024, then sank by 82.08% to $467848.8 in 2025, then soared by 201.73% to $1.4 million in 2026.
- Business Quant data shows TAK's Gains from Investment Securities at $1.4 million in Q2 2026, $4.1 million in Q1 2026, and $467848.8 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.41 Mn |
| Jun 30, 2026 | 1.41 Mn |
| Mar 31, 2026 | 4.09 Mn |
| Mar 31, 2026 | 4.09 Mn |
| Dec 31, 2025 | 467,848.85 |
| Dec 31, 2025 | 467,848.85 |
| Sep 30, 2025 | 2.27 Mn |
| Sep 30, 2025 | 2.27 Mn |
| Jun 30, 2025 | 1.73 Mn |
| Jun 30, 2025 | 1.73 Mn |
| Mar 31, 2025 | 203,192.95 |
| Mar 31, 2025 | 203,192.95 |
| Dec 31, 2024 | 2.61 Mn |
| Dec 31, 2024 | 2.61 Mn |
| Sep 30, 2024 | 6,704.14 |
| Sep 30, 2024 | 6,704.14 |
| Jun 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 85.43 Mn |
| Mar 31, 2024 | 85.43 Mn |